Science AI Journal
Medicine · Research topic

Open research questions in Rheumatoid Arthritis Research and Therapies

74 unresolved questions extracted from the limitations and future-work sections of 650 Rheumatoid Arthritis Research and Therapies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Despite advances in treatment, its pathogenesis is not fully understood; dys‑ regulated immune responses within the synovium play a central role [31, 32].

    Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway · 2026 · DOI

  • Although Tph cells are recognized as the major B-cell helpers in inflamed joints of rheumatoid arthritis (RA), the mechanisms underlying their maintenance, activation, and involvement in tissue inflammation remain poorly understood.

    Stem-like and effector peripheral helper T cells orchestrate distinct local immune responses in rheumatoid arthritis 2262732 · 2026 · DOI

  • Recently, a population of immune cells known as mucosal-associated invariant T cells (MAIT cells) has been identified in humans, although their role in RA remains unclear.

    Study of the Frequency of Mononuclear Cells Expressing MR1 Protein in the Synovial Fluid of Patients with Rheumatoid Arthritis · 2026 · DOI

  • While arthritis alone was insufficient to induce uveitis, it established a permissive ocular microenvironment that selectively enhanced the recruitment of adoptively transferred uveitogenic CD4+ T cells.

    Inflammatory arthritis disrupts ocular immune privilege by compromising blood-retinal barrier integrity and promoting uveitogenic T cell recruitment · 2026 · DOI

  • Conclusion: Anti-CCP and ESR demonstrated potential utility in the assessment of RA in this population, while the clinical relevance of anti-β2GPI remains uncertain.

    Assessment of Autoimmune and Inflammatory Biomarkers in Rheumatoid Arthritis Subjects in Port Harcourt, Nigeria · 2026 · DOI

  • However, the authors note that additional research is needed on the discriminatory ability of the DAts index across different scenarios, something Here the results flatten out somewhat after the accrual of 50% of participants but not enough to reach full exit status, suggest- ing the need for additional research on exercise and physical function in adults with RA before stability can be confirmed.

    Effects of exercise on physical function and pain in adults with rheumatoid arthritis: an exit meta-analysis of randomized controlled trials · 2026 · DOI

  • Although 5‐methylcytosine (m 5 C) modification is implicated in many diseases, its role in RA remains unclear.

    Cerium Nanoparticle‐Mediated Inhibition of the NSUN2/m <sup>5</sup> C Axis Suppresses Synovial Aggression in Rheumatoid Arthritis · 2026 · DOI

  • Future prospective longitudinal studies evaluating cumulative steroid dose, duration of NSAID exposure, treatment indication, biologic use, and radiographic outcomes are warranted to clarify the long-term impact of symptomatic therapy in the biologic era.

    Where do Glucocorticoids and Nonsteroidal Anti-Inflammatory Drugs Stand in the Treatment of Rheumatoid Arthritis in The Biologic Era? · 2026 · DOI

  • In response to the aforementioned unresolved issues, this review proposes the following future research directions: 1. Verification of complementary Mechanisms: The interaction network between triterpenoid saponins and alkaloids across ADME should be elucidated. It should also be determined whether alkaloids modulate saponin interconversion and bioavailability by regulating the gut microbiota and metabolic enzyme systems. The molecular basis underlying complementary enhancement should then be validated using addition, a comparative evaluation of different saponin–alkaloid combinations is warranted to clarify whether synergy depends on specific saponin sugar-chain architectures or on the core alkaloid scaffold. systems pharmacology framework.

    Caulophyllum robustum Maxim in the management of rheumatoid arthritis: a comprehensive review of ethnopharmacology, phytochemistry, pharmacokinetics, and pharmacological mechanisms · 2026 · DOI

  • integration across these preclinical Nevertheless, quantitative studies should prioritize remains standardized dosing/analytical platforms, absolute bioavailability estimates for representative saponins and alkaloids, and explicit linking of systemic metabolite exposure to pharmacodynamic readouts these preclinical pharmacokinetic findings will need to be validated in human studies to establish clinically relevant parameters. in RA models.

    Caulophyllum robustum Maxim in the management of rheumatoid arthritis: a comprehensive review of ethnopharmacology, phytochemistry, pharmacokinetics, and pharmacological mechanisms · 2026 · DOI

  • More studies in adherence to international guidelines (EFLM/EASI/ICAP) and the use of standardized cutoff titers (preferably ≥1:160 for pathology) as well as investigating the pathoimmunological basis of ANA-postitive healthy individuals are warranted.

    Are Antinuclear Antibodies Always Pathological? Insights from Population Data · 2026 · DOI

  • Brepocitinib, a dual TYK2/JAK1 inhibitor, has demonstrated immunomodulatory activity; however, its effects on TNF-α–driven redox imbalance, kinase signaling, and migratory behavior in RA synoviocytes remain incompletely defined.

    Dual TYK2/JAK1 Inhibition by Brepocitinib Suppresses TNF-α–Driven Oxidative Stress, PI3K/AKT/mTOR Activation and FAK-Dependent Migration in Rheumatoid Arthritis Synoviocytes · 2026 · DOI

  • Objective Programmed cell death (PCD) has become an important framework for understanding the pathogenesis of rheumatoid arthritis (RA), but the overall research landscape, intellectual base, and evolving hotspots in this field remain unclear.

    Global research trends in programmed cell death in rheumatoid arthritis from 2001 to 2025: a bibliometric analysis · 2026 · DOI

  • • Develop and embed pharmacist-inclusive, evidencebased referral guidelines: To clarify provider roles, reduce inconsistent referral patterns and improve coordinated multidisciplinary PJD care. These innovations are particularly important within the framework of South Africa’s NHI, where integrated, efficient and equitable care pathways will be essential to meet the growing burden of chronic musculoskeletal conditions. Therefore, policies that pharmacist-inclusive pathways are embedded into NHI rollout protocols. should ensure • Strengthen education interprofessional role awareness: Through higher education institutions and professional bodies to address limited collaboration and underutilisation of pharmacists and other non-physician healthcare providers (HCPs). and • Expand future referral frameworks to include dieticians and psychologists: Acknowledging in nutritional, behavioural and psychosocial management of joint disease not captured in this study. their roles • Leverage digital and artificial intelligence-enabled tools to enhance pharmacovigilance and support safe collaboration with CAM providers, particularly through the detection of herb–drug interactions.

    Management of progressive joint disorders by non-physician healthcare providers in South Africa: A mapping study to inform pharmacist integration · 2026 · DOI

  • facilitating practices among non-physician healthcare providers.43,44 Emerging strategies, implementation of including the artificial intelligence-powered pharmacovigilance systems for detecting herb–drug interactions, may support safer practice, but collaboration between robust pharmacists and non-physician healthcare providers.45 informed prescribing or require The majority of healthcare providers surveyed reported both referring to (97.7%) and receiving referrals from (89.1%) other healthcare providers, indicating a high degree of interprofessional collaboration.

    Management of progressive joint disorders by non-physician healthcare providers in South Africa: A mapping study to inform pharmacist integration · 2026 · DOI

  • Several limitations of this study should be acknowledged. First, the overall sample size of the included transcriptomic datasets was relatively limited, which may increase the risk of model overfitting and reduce statistical power. Although cross-validation was applied, independent external validation using larger multicenter cohorts is necessary to confirm generalizability. Given the limited sample size, threshold-dependent metrics such as sensitivity and specificity may be unstable and cutoff dependent; therefore, we used the AUC as the primary, thresholdindependent measure of discrimination in this study.

    Identification of diagnostic genes in rheumatoid arthritis using integrated bioinformatics, machine learning, and experimental validation · 2026 · DOI

  • The study does not examine the shared epitope and its interaction with smoking on autoantibody levels and disease manifestations in the studied RA population.

    Cigarette smoking habits and attitudes among rheumatoid arthritis patients at a tertiary centre in South Africa · 2026 · DOI

  • lysosomes before reaching Even after successful cellular internalization, inefficient endosomal escape remains a major bottleneck in RNAi therapy. A substantial fraction of delivered siRNA is degraded within the cytoplasm, preventing incorporation into the RNAinduced silencing complex (RISC).74 This intracellular trafficking challenge necessitates advanced carrier designs capable of membrane destabilization or fusion to release siRNA into the cytosol. However, enhancing endosomal escape must be carefully balanced against cytotoxicity, as excessive membrane disruption may induce cellular stress or apoptosis in non-target tissues. 10.3 Off-Target Effects and Immune Activation Advances in transcriptomics and single-cell sequencing have revealed substantial heterogeneity among RA patients, with distinct molecular endotypes defined by differential activation of IL-6/STAT3, TNF/NF-κB, or therapeutics can be interferon pathways. RNAi customized to selectively silence genes most relevant to an individual’s inflammatory profile, paving the way for precision medicine approaches.71 Such adaptability distinguishes RNAi nanomedicine from fixed-target biologics and suggests a future in which therapeutic regimens are guided by molecular diagnostics to achieve optimized disease control. RNAi therapeutics may inadvertently silence unintended transcripts due to partial sequence complementarity, leading to off-target gene modulation. Such effects can disrupt physiological pathways and complicate safety assessments.75 Furthermore, double-stranded RNA molecules may activate innate immune receptors such as TLR3, TLR7, and RIG-I, resulting in interferon infection.75,76 Although responses that mimic viral chemical modification of siRNA (e.g., 2′-O-methyl or ISSN: 2250-1177 CODEN (USA): JDDTAO Ahirwar et al. Journal of Drug Delivery & Therapeutics. 2026; 16(3):328-355 substitutions) phosphorothioate reduce immunogenicity, achieving an optimal balance between stability, specificity, and biological activity remains a central design challenge.

    RNAi-Loaded Nanocarriers Targeting the IL-6/JAK-STAT3-NF-κB Cytokine Axis in Rheumatoid Arthritis · 2026 · DOI

  • Background : Methotrexate is one of the mainstays for treating rheumatoid arthritis (RA) with a wide range of adverse drug reactions, however, it’s the relationship between adverse drug reactions and genetic polymorphism remains to be highlighted, and there is a lack of studies concerning Arabic Iraqi population regarding this aspect.

    Association of the rs1801133 and rs1801131 polymorphisms in the MTHFR gene and the adverse drug reaction of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients · 2024 · DOI

  • Limited examination of hindfoot involvement (talonavicular and subtalar joints) despite their association with functional disability and walking difficulties in RA…

    Do ankle, hindfoot, and heel ultrasound findings predict the symptomatology and quality of life in rheumatoid arthritis patients? · 2020 · DOI

  • INTRODUCTION: Although type 1 diabetes mellitus is largely associated with autoimmune thyroid disease and this entity has been recently referred to as autoimmune polyglandular syndrome type 3 variant, the autoimmune polyglandular syndrome type 3 variant in patients with rheumatoid arthritis has not been reported so far.

    Autoimmune polyglandular syndrome type 3 variant in rheumatoid arthritis · 2019 · DOI

  • Although antibodies targeting Ro52 protein/TRIM21 are commonly detected in systemic autoimmune rheumatic disorders (SARDs), their clinical significance and pathobiologic role remains incompletely understood.

    CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS · 2017 · DOI

  • DATA SYNTHESIS: We calculated a pooled odds ratio (Mantel-Haenszel methods with a continuity correction designed for sparse data) for malignancies and serious infections (infection that requires antimicrobial therapy and/or hospitalization) in anti-TNF-treated patients vs placebo patients.

    Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies · 2006 · DOI

  • Further multisite study of children recently diagnosed and with more severe forms of JRA is warranted to determine intervention needs, especially for mothers.

    Comparing Parental Distress, Family Functioning, and the Role of Social Support for Caregivers With and Without a Child With Juvenile Rheumatoid Arthritis · 2002 · DOI

  • Liver fibrosis (LF) in RA is multifactorial, but the available data are limited and the impact of methotrexate (MTX) remains controversial.

    The Liver–Heart Axis in Rheumatoid Arthritis: Associations of Liver Fibrosis, Organokines, Endothelin-1, and Cardiovascular Risk · 2026 · DOI

Most-cited papers in Rheumatoid Arthritis Research and Therapies

Most recent work

Find a gap in your own Rheumatoid Arthritis Research and Therapies sub-topic

This page shows what the Rheumatoid Arthritis Research and Therapies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
74 open questions have been extracted from the limitations and future-work passages of 650 Rheumatoid Arthritis Research and Therapies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.